FasterCures, A Center of the Milken Institute, Washington, DC 20005, USA.
Sci Transl Med. 2014 Jun 25;6(242):242cm6. doi: 10.1126/scitranslmed.3009024.
Some common challenges of biomedical product translation-scientific, regulatory, adoption, and reimbursement-can best be addressed by the broad sharing of resources or tools. But, such aids remain undeveloped because the undertaking requires expertise from multiple research sectors as well as validation across organizations. Biomedical resource development can benefit from directed consortia-a partnership framework that provides neutral and temporary collaborative environments for several, oftentimes competing, organizations and leverages the aggregated intellect and resources of stakeholders so as to create versatile solutions. By analyzing 369 biomedical research consortia, we tracked consortia growth around the world and gained insight into how this partnership model advances biomedical research. Our analyses suggest that research-by-consortium provides benefit to biomedical science, but the model needs further optimization before it can be fully integrated into the biomedical research pipeline.
一些常见的生物医学产品翻译挑战——科学、监管、采用和报销——可以通过广泛共享资源或工具来最好地解决。但是，由于这项工作需要来自多个研究领域的专业知识，并且需要在组织之间进行验证，因此这些辅助工具仍未开发。生物医学资源开发可以从定向联盟中受益——这是一种伙伴关系框架，为多个（通常是竞争的）组织提供中立和临时的合作环境，并利用利益相关者的综合智力和资源来创建多功能解决方案。通过分析 369 个生物医学研究联盟，我们跟踪了全球范围内联盟的发展，并深入了解了这种伙伴关系模式如何推动生物医学研究。我们的分析表明，联盟研究为生物医学科学带来了益处，但在将该模型完全整合到生物医学研究管道之前，还需要进一步优化。
